Search

Your search keyword '"Morra, Enrica"' showing total 9 results
Start Over Author "Morra, Enrica" Journal leukemia & lymphoma
9 results on '"Morra, Enrica"'

1. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

Author

Tedeschi, Alessandra, primary, Picardi, Paola, additional, Ferrero, Simone, additional, Benevolo, Giulia, additional, Margiotta Casaluci, Gloria, additional, Varettoni, Marzia, additional, Baratè, Claudia, additional, Motta, Marina, additional, Gini, Guido, additional, Goldaniga, Maria Cecilia, additional, Visco, Carlo, additional, Zaja, Francesco, additional, Belsito Petrizi, Valeria, additional, Ravelli, Erika, additional, Gentile, Massimo, additional, Urbano, Marina Aurora, additional, Franceschetti, Silvia, additional, Ghione, Paola, additional, Orsucci, Lorella, additional, Frustaci, Anna Maria, additional, Gaidano, Gianluca, additional, Vitolo, Umberto, additional, and Morra, Enrica, additional

Published
2015
Full Text
View/download PDF

2. Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience

Author

Nosari, Anna Maria, primary, Pioltelli, Maria Luisa, additional, Riva, Marta, additional, Marbello, Laura, additional, Nichelatti, Michele, additional, Greco, Antonino, additional, Molteni, Alfredo, additional, Vismara, Eleonora, additional, Gabutti, Cristina, additional, Volonterio, Alberto, additional, Lombardi, Pierluigi, additional, and Morra, Enrica, additional

Published
2014
Full Text
View/download PDF

4. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma

Author

Corso, Alessandro, primary, Barbarano, Luciana, additional, Mangiacavalli, Silvia, additional, Spriano, Mauro, additional, Alessandrino, Emilio P., additional, Cafro, Anna Maria, additional, Pascutto, Cristiana, additional, Varettoni, Marzia, additional, Bernasconi, Paolo, additional, Grillo, Giovanni, additional, Carella, Angelo M., additional, Montalbetti, Luigi, additional, Lazzarino, Mario, additional, and Morra, Enrica, additional

Published
2009
Full Text
View/download PDF

6. Prospective monocentric study of non-tunnelled central venous catheter-related complications in hematological patients

Author

Nosari, Anna Maria, primary, Nador, Guido, additional, Gasperi, Andrea De, additional, Ortisi, Giuseppe, additional, Volonterio, Alberto, additional, Cantoni, Silvia, additional, Nichelatti, Michele, additional, Marbello, Laura, additional, Mazza, Ernestina, additional, Mancini, Valentina, additional, Ravelli, Erica, additional, Ricci, Francesca, additional, Ciapanna, Denis, additional, Garrone, Federica, additional, Gesu, Giovanni, additional, and Morra, Enrica, additional

Published
2008
Full Text
View/download PDF

8. Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.

Author

Corso, Alessandro, Barbarano, Luciana, Mangiacavalli, Silvia, Spriano, Mauro, Alessandrino, Emilio P., Cafro, Anna Maria, Pascutto, Cristiana, Varettoni, Marzia, Bernasconi, Paolo, Grillo, Giovanni, Carella, Angelo M., Montalbetti, Luigi, Lazzarino, Mario, and Morra, Enrica

Subjects
DEXAMETHASONE, PREGNANE, MULTIPLE myeloma, B cell lymphoma, MONOCLONAL gammopathies, ETOPOSIDE, ANTINEOPLASTIC agents
Abstract

The aim of this phase II trial was to investigate the efficacy of bortezomib plus dexamethasone (Vel-Dex) as induction therapy in patients with multiple myeloma (MM) and to define the role of intensification before transplantation. Fifty-seven patients were treated with four courses of Vel-Dex, two cycles of dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP), and a single autologous transplant. Fourteen patients (25%) went off-study: seven after Vel-Dex, seven after DCEP. All patients yielded high numbers of stem cells (median CD34+ cells 7.5 × 106/kg); 54 of the 57 patients (94%) collected ≥4 × 106/kg CD34+ cells, 60% with a single leukapheresis. The overall response rate (ORR) after Vel-Dex was 86% (70% had a very good partial response [VGPR] or better) regardless of cytogenetic abnormalities and International Staging System stage (ISS). The response at the end of the two DCEP cycles remained unchanged in 35 patients (70%), worsened in 15 (20%), and improved in 5 (10%). Because of the consistent drop-out, the ORR in intention-to-treat analysis decreased significantly from 86% after Vel-Dex to 76% after DCEP, and 73% after transplantation. However, when considering the subset of 43 patients who completed the program, the ORR was 96% (complete response 39%, VGPR 41%, partial response 16%). In conclusion, Vel-Dex produces high response rates, improves stem cell collection, and overcomes the need for intensification before autologous transplantation. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

9. Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia.

Author

Nosari, Annamaria, Caimi, Teresa Maria, Zilioli, Vittorio, Molteni, Alfredo, Mancini, Valentina, and Morra, Enrica

Subjects
LETTERS to the editor, TOMOGRAPHY
Abstract

A letter to the editor is presented regarding the case of a 27-year-old woman with an history of confusion, vomiting, and headaches in which the patient was diagnosed with cerebral hemorrhage using cerebral computed tomography (CT) scan.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results